2025–2026 Hypertension Guidelines: ASC Day-of-Surgery BP Rules

The Costliest Moment in an ASC's Day

It happens before the first incision. A patient arrives for an elective outpatient procedure — a rhinoplasty, a laparoscopic hernia repair, a shoulder arthroscopy — and the intake blood pressure reads 168/102 mmHg. The CRNA consults a protocol written in 2018. The surgeon is notified. Forty minutes later, the case is cancelled, the OR block is wasted, and the patient is driving home with instructions to "follow up with your primary care doctor."

This scenario plays out thousands of times each week across ambulatory surgery centers in the United States. Preexisting hypertension is the single most common medical reason for postponing elective surgery, according to a review of the literature through May 2026 in UpToDate's perioperative hypertension management module. The same source notes that in a case-control study of 76 patients who died of a cardiovascular cause within 30 days of elective surgery, a preoperative history of hypertension was four times more likely than among matched controls — a statistic that explains why clinicians have historically erred toward caution.

But "historically" is the operative word. Between late 2025 and mid-2026, three significant guideline documents converged to fundamentally reframe what the evidence actually supports — and what it does not. For private-practice ASCs, plastic surgery groups, and the CRNAs and anesthesiologists who staff them, the gap between current protocols and current evidence is now a compliance and patient-safety issue simultaneously.

What Changed: A Guideline Cascade, Not a Single Update

Understanding the magnitude of this shift requires recognizing that it did not arrive as a single document. Three separate authoritative sources updated the landscape in sequence, each addressing a different layer of perioperative hypertension management.

First: The 2024 AHA/ACC Perioperative Cardiovascular Guideline. Published in Circulation and summarized in the Cleveland Clinic Journal of Medicine in 2025, the 2024 AHA/ACC/ACS perioperative cardiovascular management guideline superseded the 2014 version that had governed practice for a decade. Its key operational message for ASCs: strongly discourage routine preoperative cardiac testing for low-risk, asymptomatic patients, and move toward a stepwise, individualized approach to hypertension management. Testing should occur only when results will actually change management — a standard that most reflexive same-day cancellations fail to meet.

Second: The 2025 AHA/ACC Hypertension Guideline Reclassification. The American Heart Association and American College of Cardiology released updated hypertension classification criteria in 2025, introducing the PREVENT cardiovascular risk calculator, revising pharmacotherapy initiation criteria, and shifting toward lower treated blood pressure targets. A May 2026 analysis by anesthesiologists at Yale and Boston Medical Center, published in the Journal of Cardiothoracic and Vascular Anesthesia (Insler, Ortoleva, Notarianni; PMID 42250991), found that while these changes are clinically significant, perioperative surgical guidance "remains largely unchanged" within the AHA/ACC framework — meaning anesthesiologists must bridge the translational gap themselves. Most ASC protocols have not done so.

Third: The January 2026 Association of Anaesthetists / British and Irish Hypertension Society Guideline. This is the document with the most direct bedside impact. Published in Anaesthesia (McCormack et al., 2026) and summarized in clinical commentary by Anaesthesia News, it makes two operationally disruptive declarations: it resets the day-of-surgery BP postponement threshold, and it reverses longstanding ACEI/ARB hold guidance.

The New Threshold: 180/120, Not 180/110

For years, many perioperative protocols used a systolic of 180 mmHg or a diastolic of 110 mmHg as the threshold above which elective surgery should be postponed. The 2026 Association of Anaesthetists/BIHS guideline moves that diastolic threshold — the new standard for clinic-measured BP is ≥ 180/120 mmHg, with a corresponding threshold of ≥ 175/115 mmHg for home or ambulatory monitoring readings.

This is not a trivial numerical shift. The diastolic change from 110 to 120 mmHg represents a meaningful liberalization in a population where diastolic hypertension frequently drives same-day cancellations. More importantly, the guideline grounds this change in an explicit evidentiary statement: there is no clear evidence that Stage 1 or Stage 2 hypertension, in the absence of target organ damage, increases perioperative cardiovascular risk.

This conclusion has significant operational implications. A patient presenting with a BP of 158/96 mmHg — well into what is clinically classified as Stage 2 hypertension under both old and new frameworks — does not, on the basis of that number alone, carry elevated perioperative cardiovascular risk that justifies postponement. The question the protocol must answer is not "is this patient hypertensive?" but "is there evidence of target organ damage, and does this BP exceed 180/120 mmHg?" Those are categorically different clinical questions, and most current ASC intake workflows do not distinguish between them.

For ambulatory surgery centers operating on tight OR block schedules, the practical implication is clear: a significant proportion of current same-day cancellations based on BP readings between 140/90 and 179/119 mmHg — with no sign of end-organ involvement — are no longer supported by the best available evidence.

The ACEI/ARB Hold Reversal: Flipping the #1 Medication Protocol

Ask any CRNA or anesthesiologist what the most contentious same-day medication question is, and the answer is nearly always the same: do we hold the ACE inhibitor or ARB? For decades, the dominant practice was to hold these agents the morning of surgery to reduce the risk of intraoperative hypotension — a reasonable precaution when the evidence was sparse.

The evidence is no longer sparse. The 2026 Association of Anaesthetists/BIHS guideline, drawing on moderate-quality evidence including the 'Stop-or-Not' trial, now issues a moderate recommendation to continue ACE inhibitors and ARBs through the morning of surgery, reversing the longstanding hold practice. This recommendation appears in both the primary guideline published in Anaesthesia and the operational commentary in Anaesthesia News.

The clinical rationale is straightforward: patients who hold their ACEI or ARB arrive with less controlled blood pressure, which paradoxically increases the likelihood that the day-of-surgery BP reading will trigger a cancellation threshold. Meanwhile, the feared intraoperative hypotension risk from continuation has not been borne out as a dominant outcome driver in controlled trial data. The "protective hold" may, in a subset of patients, be creating the very problem it was designed to prevent.

For ASC administrators and medical directors, this reversal requires an immediate protocol audit. If your current pre-admission instructions tell patients taking lisinopril, ramipril, losartan, or valsartan to skip their morning dose, that instruction is now at odds with a January 2026 guideline from two major professional societies. Updating that instruction is a documentation and informed-consent issue, not just a clinical preference.

The Translational Gap: Where Most ASCs Are Right Now

The JCVA analysis by Insler, Ortoleva, and Notarianni captures the core problem precisely: the 2025 AHA/ACC hypertension reclassification introduces real changes in how patients are categorized and treated in the outpatient setting, but perioperative surgical guidance in that framework remains largely on expert opinion, leaving anesthesiologists to bridge the translational gap between cardiology guidelines and the OR door.

That gap is widest at the level of the ASC — particularly private-practice centers without academic medical center infrastructure, protocol review committees, or dedicated anesthesia department leadership. A plastic surgery ASC running cosmetic and reconstructive cases, a GI center handling endoscopy and minor surgical procedures, an ophthalmology center doing cataract and LASIK volume — none of these facilities typically has a standing mechanism to track guideline updates in perioperative hypertension and translate them into revised intake protocols within weeks of publication.

The result is a dual liability: cancelling cases that do not need to be cancelled (a revenue and patient-experience failure), while potentially missing the cases that genuinely do require postponement because the protocol is not calibrated to the correct clinical signals — namely, evidence of target organ damage rather than a raw BP number.

Consider a textbook scenario that illustrates the asymmetry: a 61-year-old patient presents for outpatient abdominoplasty with a BP of 172/108 mmHg, no history of stroke, renal disease, or heart failure, normal ECG, and stable chronic hypertension on amlodipine and losartan (which was held per standing instructions). Under the prior 180/110 framework, this patient is right at the edge of postponement. Under the 2026 guidance, this patient does not meet the postponement threshold, the medication hold may have artificially elevated the reading, and the absence of target organ damage means proceeding — with appropriate intraoperative monitoring — is defensible. The protocol, not the patient, is the problem.

What an Updated ASC Protocol Must Address

Translating the 2025–2026 guideline cascade into an operational ASC workflow requires addressing at least five discrete elements:

• Updated BP postponement threshold: Replace any protocol language referencing 180/110 with the current standard of ≥ 180/120 mmHg (clinic) or ≥ 175/115 mmHg (home/ambulatory). Ensure the diastolic threshold is explicit — it is the number most likely to have changed in your existing document.
• Target organ damage screening: The decision to postpone should hinge on evidence of end-organ involvement — renal impairment, hypertensive retinopathy, LVH, prior stroke — not BP staging alone. Intake workflows should prompt for these signals specifically.
• ACEI/ARB pre-admission instructions: Audit and revise any patient instructions directing ACEI or ARB hold the morning of surgery. The 2026 Association of Anaesthetists/BIHS guideline recommends continuation based on moderate evidence. Document the rationale for the change.
• Measurement standardization: The 2026 guideline differentiates between clinic-measured and home/ambulatory readings with different thresholds. Protocols should specify measurement technique — seated, rested, appropriate cuff size, bilateral if first reading is elevated — to ensure the number triggering a decision is a valid one.
• Risk stratification alignment with 2024 AHA/ACC perioperative guidance: The 2024 AHA/ACC perioperative cardiovascular guideline and its Cleveland Clinic Journal of Medicine summary both reinforce that low-risk, asymptomatic patients should not be reflexively referred for cardiac testing. The BP decision should be part of a broader, individualized risk assessment — not an isolated number-based gatekeeping function.

This is precisely where tools like VeriOp.ai are designed to close the gap. Rather than relying on a static PDF protocol that goes unrevised for years, an evidence-based clinical decision support platform — designed to meet criteria for Clinical Decision Support under the 21st Century Cures Act — can surface the correct threshold, flag target organ damage risk factors, and guide ACEI/ARB continuation decisions at the point of care, in real time, for every patient. The VeriOp.ai validation study details how this approach performs against current perioperative evidence standards.

The Bottom Line for ASC Leaders

The blood pressure rules have changed. Not incrementally — structurally. The 2026 Association of Anaesthetists/BIHS guideline, the 2025 AHA/ACC hypertension reclassification, and the 2024 AHA/ACC perioperative cardiovascular guideline collectively establish a new standard of care that most ambulatory surgery centers are not yet practicing.

The cost of inaction is measured in two directions. Unnecessary cancellations — cases postponed for BP readings between 140/90 and 179/119 in patients without target organ damage — represent lost revenue, disrupted patient care, and protocol-driven harm to facility reputation. But the inverse error is equally serious: a protocol that applies a lower, outdated threshold uniformly may create false confidence that the genuinely high-risk patients (BP ≥ 180/120 with unreported renal disease, for example) are being caught.

The JCVA analysis is right that anesthesiologists bear the translational burden here. But in the ASC setting, that burden is shared by medical directors, facility administrators, and the CRNAs who make the go/no-go call at 7:15 in the morning. All three need the same updated framework — and a system that keeps it current as the evidence continues to evolve.

VeriOp.ai was built for exactly this moment: when guidelines move faster than protocols, and the gap between the two lands in the pre-op bay.